Assessing the Durability of Entecavir-Treated Hepatitis B Using Quantitative HBsAg

Abstract

The serum qHBsAg level off-therapy can predict durability of ETV-treated CHB patients. It may guide clinicians to select which patients can maintain sustained viral suppression or need retreatment after discontinuing ETV treatment.